Does genomic tumour profiling treat cancer of unknown primary?

Cancer of unknown primary means cancer has been found, but the original site has not been identified after clinical assessment and testing. Profiling examines molecular features in a tumour sample. The pattern may suggest a tissue of origin or identify a feature that makes a particular treatment worth discussing, although it may not provide a definite answer.

Results need to be interpreted with scans, pathology, symptoms and examination. A molecular finding is not itself a treatment, and a result without a useful target does not mean that care stops. Your team can still use the overall clinical picture to plan treatment and follow-up.

Ask your oncology team what question the test is intended to answer and whether the available tumour sample is suitable. Discuss how a possible tissue-of-origin suggestion would be checked against the rest of your results. Ask which treatment decisions could change, when the report is expected, and what the plan is if profiling remains inconclusive.

Tell your care team promptly about new pain, increasing breathlessness, persistent vomiting, confusion, weakness, fever or difficulty eating and drinking. Seek urgent help for severe breathing difficulty, heavy bleeding, collapse or sudden neurological changes. These warning signs require clinical assessment and should not be attributed to an outstanding profiling result.

Ask what tissue is being analysed, whether the test looks for tumour mutations, tissue origin or both, and how reliable each type of finding may be in your situation. Ask who will review the report, whether a specialist pathology discussion is planned, and how the result fits with your current treatment options.